Metastatic disease to the breast: the Washington University experience by Vaughan, Aislinn et al.
BioMed  Central
Page 1 of 8
(page number not for citation purposes)
World Journal of Surgical Oncology
Open Access Research
Metastatic disease to the breast: the Washington University 
experience
Aislinn Vaughan1, Jill R Dietz1, Jeffrey F Moley1,2, Mary K DeBenedetti1, 
Rebecca L Aft1,2, William E Gillanders1, Timothy J Eberlein1, Jon Ritter3 and 
Julie A Margenthaler*1
Address: 1Department of Surgery, Washington University School of Medicine, St. Louis, MO, USA, 2Department of Surgery, John Cochran Veterans 
Hospital, St. Louis, MO, USA and 3Department of Pathology, Washington University School of Medicine, St. Louis, MO, USA
Email: Aislinn Vaughan - vaughana@wudosis.wustl.edu; Jill R Dietz - dietzj@wudosis.wustl.edu; Jeffrey F Moley - moleyj@wudosis.wustl.edu; 
Mary K DeBenedetti - debenedettim@wudosis.wustl.edu; Rebecca L Aft - aftr@wudosis.wustl.edu; 
William E Gillanders - gillandersw@wudosis.wustl.edu; Timothy J Eberlein - eberleint@wudosis.wustl.edu; Jon Ritter - ritterj@path.wustl.edu; 
Julie A Margenthaler* - margenthalerj@wudosis.wustl.edu
* Corresponding author    
Abstract
Background: Metastases to the breast occur rarely, but may be increasing in incidence as patients
live longer with malignant diseases. The aim of this study is to characterize metastatic disease to
the breast and to describe the management and prognosis of patients who present with this
diagnosis.
Methods: A retrospective review of our institution's pathology and breast cancer databases was
performed in order to identify patients with breast malignancies that were not of primary breast
origin. Chart review provided additional information about the patients' primary malignancies and
course of illness.
Results: Between 1991 and 2006, eighteen patients with metastatic disease to the breast of non-
hematologic origin were identified and all had charts available for review. Among the 18 patients
with disease metastatic to the breast, tissues of origin included 3 ovarian, 6 melanoma, 3 medullary
thyroid, 3 pulmonary neuroendocrine, 1 pulmonary small cell, 1 oral squamous cell, and 1 renal cell.
Overall mean survival after diagnosis of metastatic disease to the breast was 22.4 months.
Treatment of metastases varied and included combinations of observation, surgery, radiation, and
chemotherapy. Five patients (27.8%) required a change in management of their breast disease for
local control.
Conclusion: Due to the variable course of patients with metastatic disease, a multi-disciplinary
approach is necessary for each patient with disease metastatic to the breast to determine optimal
treatment. Based on our review, many patients survive for long periods of time and local treatment
of metastases to the breast may be beneficial in these patients to prevent local complications.
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Background
Metastatic disease to the breast occurs rarely, but may
become an increasingly frequent diagnosis as patients
continue to live longer with malignant diseases. Breast
carcinoma continues to be the most common malignancy
in women in the United States and constitutes approxi-
mately 30% of all female malignancies. Metastatic neo-
plasms to the breast account for 0.5–6.6% of all
malignant mammary tumors and, like primary breast can-
cer, occur more frequently in women. Metastatic lesions
to the breast tend to be painless discrete masses and are
commonly associated with axillary adenopathy [1]. As a
result, diagnostic dilemmas often arise in differentiating
these rare neoplasms metastatic to the breast from the sig-
nificantly more common primary breast carcinomas.
Series with the highest rates of metastatic disease to the
breast are due to the inclusion of systemic malignancies,
including both lymphomas and leukemias [1,2]. Very lit-
tle is known about the prognosis or treatment of patients
with non-hematologic metastases to the breast. The cur-
rent study aims to investigate our institutional series of
patients with these rare malignancies in order to identify
methods of management and overall prognosis.
Methods
An Institutional Review Board protocol was approved to
retrospectively review the surgical oncology and pathol-
ogy databases at Washington University School of Medi-
cine from January 1, 1991 through December 31, 2006 in
order to identify patients with neoplasms metastatic to the
breast. After identifying potential patients, pathology
reports and medical charts were reviewed to identify those
patients who had documented elsewhere primaries with
pathologically identified metastases to the breast. Patients
with systemic malignancies, including lymphomas and
leukemias, were excluded. Patients whose primary malig-
nancy could not be conclusively identified were excluded.
Eighteen patients were identified fulfilling these criteria,
and their medical records were extensively reviewed. Data
collected included patient demographics and details of
their primary malignancies and treatment courses. Infor-
mation regarding the detection, pathology, and treatment
of the secondary breast neoplasm was also recorded.
Descriptive statistics were utilized for data presentation.
Results
Eighteen patients were identified with primary malignan-
cies metastatic to the breast between 1991 and 2006
(Table 1). These patients represented 0.2% of the total
number of patients treated for breast malignancies during
the study period. Six patients had malignant melanoma, 3
had medullary thyroid carcinoma, 3 had ovarian carci-
noma, 3 had pulmonary neuroendocrine carcinoma, 1
had small cell carcinoma of the lung, 1 had squamous cell
carcinoma of the tongue, and 1 had renal cell carcinoma.
When reviewing all 18 patients, the average time between
initial diagnosis of the primary malignancy and develop-
ment of a metastasis to the breast was 60.9 months (range
0–276 months). Mean length of survival after being diag-
nosed with disease metastatic to the breast was 22.4
months (range 5–120 months). Six of the 18 patients
were alive at follow-up with an average of 31.5 months
having elapsed since being diagnosed with a breast metas-
tasis. Of the 12 patients who have died of their diseases,
the mean survival time after developing a breast metasta-
sis was 17.8 months (range 5–37 months).
The method of diagnosis and the patients' treatments var-
ied considerably, as did their disease courses (Table 2).
Twelve of the patients had routine breast imaging per-
formed, including mammograms and/or ultrasounds.
Examples of representative mammogram and ultrasound
images from one of our patients are shown in Figures 1, 2,
3, 4. Seven patients had a breast core needle biopsy per-
formed for diagnostic purposes without further surgical
excision; all 7 patients had widespread metastatic disease.
Eleven patients underwent surgical excision of the meta-
static breast lesion, though the indications and control of
the underlying primary disease varied widely. Four
patients had an isolated breast metastasis and underwent
complete surgical excision of the breast metastasis for cur-
ative intent. Five patients had either a partial mastectomy
or an excisional biopsy of the metastatic breast lesion; all
5 patients had widespread metastatic disease and the rea-
sons for excision were unclear from the retrospective
review. One patient with metastatic ovarian cancer
required mastectomy for local control of a rapidly enlarg-
ing tumor. One patient had an excisional biopsy to differ-
entiate between primary breast carcinoma and metastatic
medullary thyroid carcinoma.
A change in management occurred in 5 of the 18 patients
(27.8%) due to local breast complications. One patient
with ovarian cancer metastatic to the breast was initially
managed conservatively after a core needle biopsy was
performed for diagnosis, but subsequently required mas-
tectomy due to large tumor burden and local wound com-
plications. One patient required an additional excisional
biopsy when a metastatic melanoma recurred in the
breast. A second patient with malignant melanoma meta-
static to the breast had a local recurrence after partial mas-
tectomy and required simple mastectomy for treatment.
One patient with metastatic pulmonary neuroendocrine
carcinoma required radiation treatment to the breast after
a breast metastasis recurred following excisional biopsy.
One male patient with metastatic renal cell carcinoma was
being observed after a core needle biopsy diagnosed a
breast metastasis. The mass enlarged and became tender
and was then treated with radiation therapy resulting in
local control with a decrease in size of the mass.World Journal of Surgical Oncology 2007, 5:74 http://www.wjso.com/content/5/1/74
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Patient treatment varied according to the type of primary
malignancy diagnosed. Six patients had malignant
melanoma. The mean time between diagnosis of
melanoma and development of a breast metastasis was
78.2 months (range 9–276 months). The mean survival
after the diagnosis of a metastasis to the breast was 19.7
months (range 5–38 months). All presented with palpa-
ble breast masses. Two patients had core biopsies for diag-
nosis and no further local treatment to the breast, and
neither of them developed local breast complications
prior to their deaths. Four of the 6 patients with
melanoma underwent resection of the secondary breast
malignancy. One patient had a partial mastectomy with
negative surgical margins; she succumbed to her meta-
static disease 5 months later without evidence of local
breast recurrence. One had an excisional biopsy for diag-
nosis followed by an ipsilateral axillary node dissection
but developed a locoregional recurrence in the breast at
20 months post-excision, requiring a subsequent exci-
sional biopsy; there was no evidence of breast recurrence
at the time of death. One patient had an excisional biopsy
with frozen section evaluation at the time of resection of
a primary site local recurrence. Intraoperative pathology
confirmed metastatic malignant melanoma and partial
mastectomy with negative margins was performed at that
time. She subsequently developed a recurrence in both
her primary site and breast. At that time she had wide
local excision of her primary recurrence as well as simple
mastectomy for her breast recurrence. She died of progres-
sive metastatic disease more than 18 months after mastec-
tomy. One patient underwent modified radical
mastectomy after an excisional biopsy diagnosed the
breast metastasis and was free of a breast recurrence at the
time of her death.
Three patients had medullary thyroid carcinoma meta-
static to the breast, and all 3 had MEN syndrome. The
mean time between diagnosis of their thyroid malignan-
cies and development of a breast metastasis was 140.7
months (range 14–264 months). The mean survival after
diagnosis of the breast metastasis was 51 months (range
16–120 months). All presented with palpable masses.
One patient had a core needle biopsy only and no addi-
tional local treatment and died of the primary malignancy
18 months later with the breast metastasis intact. One
patient had an excisional biopsy and died of the primary
malignancy 16 months later without evidence of breast
recurrence. One patient had two excisional biopsies of
breast metastases and is alive at follow-up, but has suf-
fered an additional locoregional recurrence in the breast;
no further local therapy is planned.
Three patients with ovarian carcinoma presented with
metastases to the breast. The mean time between diagno-
sis of ovarian carcinoma and development of a breast
metastasis was 33.7 months (range 3–84 months). The
mean survival after development of the breast metastasis
was 19 months (range 6–37 months). One patient had a
Table 1: Characteristics of patients with metastatic disease to the breast
Primary 
malignancy
Age at 
Diagnosis 
(years)*
Time to 
metastasis 
(months)**
Vital Status Secondary 
Survival 
(months)***
Breast 
Laterality
Breast Surgical 
Treatment
Melanoma 26 48 Dead 5 Left Excision
Melanoma 23 276 Dead 6 Right Biopsy only
Melanoma 59 34 Dead 9 Left Biopsy only
Melanoma 83 9 Dead 24 Right Mastectomy
Melanoma 70 36 Dead 36 Right Excision, ALND
Melanoma 38 66 Dead 38 Left MRM
Thyroid 13 264 Dead 16 Left Excision
Thyroid 17 144 Alive with disease 18 Left Biopsy only
Thyroid 29 14 Alive with disease 120 Bilateral Excision
Ovarian 59 84 Dead 6 Right Excisional biopsy
Ovarian 63 14 Alive with disease 14 Right MRM
Ovarian 49 3 Dead 37 Right Excisional biopsy
Lung (small cell) 83 0 Alive with disease 21 Right Biopsy only
Lung (neuroendocrine) 30 38 Alive with disease 7 Left Excision
Lung (neuroendocrine) 35 0 Alive with disease 9 Bilateral Biopsy only
Lung (neuroendocrine) 28 8 Dead 17 Right Excision
Tongue 48 10 Dead 8 Right Biopsy only
Kidney 67 48 Dead 12 Left Biopsy only
ALND = axillary lymph node dissection; MRM = modified radical mastectomy
*Age at diagnosis of primary malignancy
** Time between primary malignancy diagnosis and the development of a breast metastasis
***Survival after the diagnosis of a breast metastasis until death or study follow-up.World Journal of Surgical Oncology 2007, 5:74 http://www.wjso.com/content/5/1/74
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core needle biopsy for diagnosis with no initial plans for
further local therapy due to her widely metastatic ovarian
disease. She subsequently developed progressive enlarge-
ment of the breast metastasis necessitating a palliative
modified radical mastectomy for local control. Two
patients underwent excisional biopsy with negative mar-
gins and were free of breast recurrence at the time of
death.
Three patients had pulmonary neuroendocrine carci-
noma. One patient presented with a breast metastasis 38
months after her original diagnosis. She subsequently
underwent a partial mastectomy and is still living 7
months later with no evidence of breast disease. The sec-
ond patient presented with bilateral breast masses and
was initially thought to have bilateral invasive ductal can-
cer after bilateral core needle biopsies. Further review of
pathology identified an immunohistochemical profile
Left and right mediolateral oblique views from a 35 year-old  patient who presented with bilateral palpable breast masses Figure 2
Left and right mediolateral oblique views from a 35 year-old 
patient who presented with bilateral palpable breast masses. 
She was found to have metastatic disease to her breast from 
a lung neuroendocrine carcinoma.
Table 2: Treatment and outcome of metastases to the breast
Primary malignancy Breast 
Imaging
BI-RADS 
category
Other 
metastases
Diagnostic 
Modality
Breast Surgical 
Treatment
Excision 
margins
Local 
recurrence
Melanoma MMG, U/S 4 Widespread CNB None N/A N/A
Melanoma MMG, U/S 5 Widespread CNB None N/A N/A
Thyroid MMG 4 Widespread CNB None N/A N/A
Lung (small cell) MMG, U/S 5 Widespread CNB None N/A N/A
Lung (neuroendocrine) MMG, U/S 4 Widespread CNB None N/A N/A
Tongue MMG 5 Widespread CNB None N/A N/A
Kidney None N/A Widespread CNB None N/A N/A
Melanoma MMG, U/S 4 Locoregional Excision Excision Negative Yes
Melanoma None N/A No Excision Excision, ALND Negative Yes
Melanoma None N/A No Excision MRM Negative No
Melanoma None N/A Widespread FNA Excision Negative No
Thyroid MMG, U/S 6 Widespread Excision Excision Negative Yes
Thyroid MMG, U/S 3 Widespread Excision Excision Negative No
Ovarian None N/A Widespread Excision Excision Positive No
Ovarian MMG, U/S 4 Widespread CNB MRM Negative No
Ovarian MMG, U/S 4 No Excision Excision Negative No
Lung (neuroendocrine) MMG, U/S 4 Widespread CNB Excision Positive No
Lung (neuroendocrine) None N/A Widespread Excision Excision Negative Yes
BI-RADS = Breast Imaging Reporting and Data System; MMG = mammogram; U/S = ultrasound; N/A = not available and/or applicable; FNA = fine 
needle aspiration biopsy; CNB = core needle biopsy; ALND = axillary lymph node dissection; MRM = modified radical mastectomy
Left and right craniocaudal mammogram views from a 35  year-old patient who presented with bilateral palpable breast  masses Figure 1
Left and right craniocaudal mammogram views from a 35 
year-old patient who presented with bilateral palpable breast 
masses. She was found to have metastatic disease to her 
breast from a lung neuroendocrine carcinoma.World Journal of Surgical Oncology 2007, 5:74 http://www.wjso.com/content/5/1/74
Page 5 of 8
(page number not for citation purposes)
consistent with a neuroendocrine carcinoma and subse-
quently a lung primary, as well as diffuse visceral metas-
tases, were identified. Figures 5, 6, 7 show her diagnostic
breast core needle biopsy histology. This patient has had
no surgical treatment of her breast metastases and is cur-
rently living with stable breast disease 9 months later. The
third patient developed the breast metastasis 8 months
after her original diagnosis and underwent an excisional
biopsy. She developed another breast metastasis 4
months after the first was excised, and this lesion was
treated with radiation therapy and no additional surgery.
She died of her disease 17 months after developing her
initial breast metastasis.
One patient had pulmonary small cell carcinoma, with a
breast mass as the first presenting symptom. Pathological
analysis of a core needle biopsy revealed a small cell carci-
noma and staging studies identified a lung primary. She
has had no further local breast treatment and is living 21
months later with widely metastatic disease.
One patient initially presented with a squamous cell car-
cinoma of the tongue. She developed a palpable breast
mass 10 months later and had a core needle biopsy per-
formed confirming metastatic squamous cell carcinoma.
She had diffuse nodal and visceral metastases and died of
her disease 8 months after developing the breast metasta-
sis.
One patient had a renal cell carcinoma. This is the only
male patient identified in our review, and he developed
his breast metastasis 48 months after his original diagno-
sis. He had a core needle biopsy for diagnosis followed by
radiation treatment to his breast metastasis. He had mul-
tiple pulmonary metastases, as well, and died of his dis-
ease 12 months after developing the breast metastasis.
Discussion
Metastatic disease to the breast continues to be a rare
manifestation of primary non-hematologic malignancies.
It is predominantly a disease of women, similar to that
observed with primary breast cancers. As systemic treat-
ment for patients with metastatic malignancies becomes
more efficacious and overall survival improves, the emer-
gence of secondary breast neoplasms is also likely to
increase in number. The majority of information on this
topic in the literature consists of case reports and small
case series [1-9]. The inability to predict either an individ-
ual patient's longevity or whether a patient will develop
local complications of his or her metastatic disease makes
treatment decision-making difficult. There is minimal
information in the literature regarding prognosis of
patients with disease metastatic to the breast [1]. For our
group of patients, the mean survival time after being diag-
nosed with a breast metastasis was 22.4 months. Mean
Left breast ultrasound from a 35 year-old patient with bilat- eral palpable breast masses Figure 4
Left breast ultrasound from a 35 year-old patient with bilat-
eral palpable breast masses. The ultrasound documented a 
42 × 36 mm hypoechoic mass. She was found to have meta-
static disease to her breast from a lung neuroendocrine car-
cinoma.
Right breast ultrasound from a 35 year-old patient with bilat- eral palpable breast masses Figure 3
Right breast ultrasound from a 35 year-old patient with bilat-
eral palpable breast masses. The ultrasound documented a 
19 × 14 mm hypoechoic mass. She was found to have meta-
static disease to her breast from a lung neuroendocrine car-
cinoma.World Journal of Surgical Oncology 2007, 5:74 http://www.wjso.com/content/5/1/74
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survival following development of a breast metastasis was
similar for most of our patients regardless of their primary
tumor origin, except for patients with a primary medullary
thyroid cancer who had a prolonged mean survival (51
months).
The clinical and mammographic features of secondary
breast neoplasms have been described [2,10,11]. The
lesions are typically mobile, well demarcated, firm, but
they lack microcalcifications or skin changes that are often
associated with primary breast carcinomas [10,11]. They
can be confused radiologically for benign breast disease
due to their often well-circumscribed nature and/or pres-
ence of bilateral or multiple lesions. The difficulty in inter-
preting these imaging characteristics were evident in our
patients, as only 3 of the 18 patients had a BI-RADS cate-
gory 5 designation. Thus, a detailed personal history of
malignancy is vital information for the mammographer in
order to fully evaluate breast lesions arising in patients
with prior or current malignancies of any type.
Two of our patients developed breast masses as their first
indication of a primary malignancy. Interestingly, both
patients had a pulmonary malignancy as their primary
tumors (1 small cell and 1 neuroendocrine). Toombs and
Kalisher [1] published a report on 12 patients with small
cell lung carcinoma who developed breast metastases. Six
of their patients had a palpable breast mass as the initial
presenting sign/symptom. The overall survival in their
study was 17.8 months, which was significantly longer
than previously published reports, likely reflecting
improvements in systemic treatment that had occurred in
the 30 years previous to their report. Significant improve-
ments in systemic therapy are likely to continue to
lengthen overall survival, as evidenced by our patient with
small cell lung carcinoma and a breast metastasis who is
currently alive at follow-up (21 months).
The treatment of patients with these metastatic breast
lesions varied widely in our study. While the majority of
our patients did undergo some type of formal resection of
their breast metastases (11 of 18 overall, 61%), only 4
patients (22%) had a resection for curative intent. In addi-
tion, 5 of the 18 patients (27.8%) required a change in
their initial management due to the secondary breast
malignancy. Why some of our patients with secondary
breast neoplasms were offered surgical excision of the
tumor in the face of widely metastatic disease, while oth-
ers were not, is unclear. Perhaps patients who have a bet-
ter initial prognosis, as subjectively evaluated by the
physician (low tumor burden, clearance of metastases
with adjuvant therapy, minimal comorbidities, younger
age), were more likely to be given the option of surgery.
We know very little about the complex physician and
patient treatment decision-making processes for patients
with secondary breast neoplasms, and we cannot infer a
causal relationship based on this retrospective study.
One theory for the use of surgical excision of a breast
metastasis may be related to the primary tumor biology
and the extent of metastatic disease. Physicians may be
Sections of the left breast mass core needle biopsy specimen  shown in Figure 5 were positive for chromogranin A immu- nostaining Figure 6
Sections of the left breast mass core needle biopsy specimen 
shown in Figure 5 were positive for chromogranin A immu-
nostaining.
Histological sections from a 35 year-old patient with bilateral  palpable breast masses Figure 5
Histological sections from a 35 year-old patient with bilateral 
palpable breast masses. A representative hematoxylin and 
eosin section of the left breast mass core needle biopsy spec-
imen is shown at 600 × magnification. The tumor is com-
posed of diffuse sheets of small polygonal cells with nuclear 
molding, scant cytoplasm, brisk apoptotic rate, and numerous 
mitoses. Tumor cells were negative for estrogen receptor, 
progesterone receptor, and Her2neu (slides not shown).World Journal of Surgical Oncology 2007, 5:74 http://www.wjso.com/content/5/1/74
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more inclined to recommend resection of a breast metas-
tasis for patients with indolent primary tumors, patients
with an isolated metastasis, or patients with primary
tumors to which adjuvant systemic and radiation thera-
pies have little effect. Patients with metastatic melanoma
or medullary thyroid cancer often undergo metastasec-
tomy, as shown in previous reports [12,13] and in the cur-
rent study. For patients with widely metastatic cancer,
surgical debulking may play a part in the treatment of
these patients. The association between a decrease in
tumor burden and improvement in survival is observed in
several aggressive metastatic cancers, such as ovarian,
renal, colorectal, and gastric cancers, which are managed
with surgical debulking before the receipt of adjuvant sys-
temic chemotherapy [14-24]. Surgical debulking can help
restore the patient's immune system, improve their nutri-
tional status, decrease the seeding of metastases, and
increase the efficacy of adjuvant treatment [15]. A lower
tumor burden makes chemotherapy more effective and
can limit the emergence of chemoresistant cell lines [18].
Surgery also removes necrotic tumor areas that may be
inaccessible to drugs [15]. However, one must use caution
in applying these theories across varying carcinomas. In
the case of colorectal and gastric cancer, this benefit is
negated by incomplete metastasectomy [20-24]. In addi-
tion, the impact of tumor-specific biological factors, such
as route of metastatic spread, responsiveness to systemic
therapies, and growth kinetics differ widely among vari-
ous types of metastatic cancers and may not be generaliz-
able across types.
Another factor that could contribute to the use of surgical
excision of a secondary breast neoplasm is the disease-free
interval between diagnosis of the primary tumor and
emergence of the breast metastasis. This has been well
studied in the colorectal literature, and patients with syn-
chronous or metachronous liver metastases have a poorer
overall survival following liver metastasectomy compared
to patients who develop a liver metastasis years after their
initial colorectal cancer diagnosis [21-23]. Georgiannos et
al. [8] demonstrated an average time between the primary
malignancy diagnosis and the development of a breast
metastasis of 2 years. This is significantly shorter than in
the current study where the average was greater than 5
years. We attribute this to the fact that we excluded hema-
tologic malignancies, whereas the former study did not.
Finally, surgical excision of metastatic disease to the breast
may be performed for purely palliative indications. This
line of reasoning parallels the surgical treatment approach
for patients with metastatic primary breast cancer. Histor-
ically, surgical treatment for metastatic (stage IV) primary
breast cancer has been reserved only for cases when the
primary tumor has led to complications, such as skin
ulceration, infection with foul drainage, and life-threaten-
ing bleeding [25]. Improvements in systemic therapies for
the various primary tumors in our study population may
result in longer life expectancies and increased risk of local
wound complications from the metastases to the breast.
The relatively low morbidity and mortality associated
with surgical resections for breast malignancies (in con-
trast to surgical debulking for ovarian, colon, gastric, and
renal cell cancers) may result in a higher likelihood that
surgical resection is recommended in patients with incur-
able metastatic disease.
The results of this single-institution study must be inter-
preted in light of its limitations. Limitations of our study
include its retrospective analysis approach, the limited
number of patients precluding quantitative statistical
analysis, and the variability in types and methods of local
and systemic therapies utilized. Another limitation of our
study was the heterogeneity of our patient population.
Wide variations in tumor origin, metastatic burden, and
characteristics of the breast tumor metastases exist in the
patient population.
Conclusion
While systemic therapy remains the cornerstone for meta-
static malignancies, locoregional control of disease meta-
static to the breast may play a vital role in select patients.
As patients continue to live longer with malignant disease,
Sections of the left breast mass core needle biopsy specimen  shown in Figure 5 were positive for synaptophysin immunos- taining Figure 7
Sections of the left breast mass core needle biopsy specimen 
shown in Figure 5 were positive for synaptophysin immunos-
taining. Identical histological features were seen on the con-
tralateral breast core biopsy specimen. The immunostain 
results suggested a neuroendocrine carcinoma, rather than a 
primary breast adenocarcinoma. Staging exams confirmed a 
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individualized, multidisciplinary consideration must be
given to the use of surgery to control local breast disease.
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